Cel-Sci: Pivotal Phase 3 Trial Underway for Innovative Immunotherapy

Apr. 5, 2016
Dave Gentry, host of "The RedChip Money Report", interviews Geert Kersten, CEO of Cel-Sci (NYSE MKT: CVM). CEL-SCI's work is focused on finding the best ...

 Read More

Bloomberg TV Show

CEO Interviews

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market